Hepatitis B virus reactivation in a case of non-Hodgkin's lymphoma treated with chemotherapy and rituximab: necessity of prophylaxis for hepatitis B virus reactivation in rituximab therapy.
A patient with Non-Hodgkin's lymphoma is reported, in which reactivation of the hepatitis B virus was achieved from treatment with rituximab. The patient's HBs antigens were positive on admission, and she tested positive for HBs, HBe, and HBc antibodies, and negative for the HBe antigens. She was treated with a regimen of three courses of rituximab-containing anti-cancer drugs and one course of combined anti-cancer drugs. Throughout these chemotherapy courses, prednisolone was not given. After the fourth course of chemotherapy with the third rituximab she developed hepatic dysfunction, and the serum titers of HBs and HBc antibodies suddenly decreased. After administration of lamivudine, however, she gradually recovered from liver failure.
Tsutsumi
Yutaka
Y
Department of Internal Medicine, Hakodate Municipal Hospital, Hakodate, Japan.
Kawamura
Takahito
T
Saitoh
Shin
S
Yamada
Masahiro
M
Obara
Shinji
S
Miura
Takuya
T
Kanamori
Hiroe
H
Tanaka
Junji
J
Asaka
Masahiro
M
Imamura
Masahiro
M
Masauzi
Nobuo
N
D000368:Aged; D000911:Antibodies, Monoclonal / Q000009:adverse effects* / Q000627:therapeutic use; D058846:Antibodies, Monoclonal, Murine-Derived; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects* / Q000627:therapeutic use; D005260:Female; D006509:Hepatitis B / Q000139:chemically induced / Q000188:drug therapy / Q000517:prevention & control; D006515:Hepatitis B virus / Q000502:physiology*; D006801:Humans; D019259:Lamivudine / Q000627:therapeutic use; D017093:Liver Failure / Q000139:chemically induced / Q000821:virology; D008228:Lymphoma, Non-Hodgkin / Q000150:complications / Q000188:drug therapy*; D000069283:Rituximab; D012698:Serologic Tests; D014775:Virus Activation / Q000187:drug effects*
D000911:Antibodies, Monoclonal; D058846:Antibodies, Monoclonal, Murine-Derived; D019259:Lamivudine; D000069283:Rituximab